LINACLOTIDE - Generic Drug Details

What are the generic drug sources for linaclotide and what is the scope of freedom to operate?

Linaclotide is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, Mylan, and Abbvie, and is included in three NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Linaclotide has two hundred and twenty-three patent family members in forty-six countries.

There are ten drug master file entries for linaclotide. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for LINACLOTIDE

International Patents:	223
US Patents:	7
Tradenames:	2
Applicants:	3
NDAs:	3
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	29
Clinical Trials:	47
Patent Applications:	1,007
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LINACLOTIDE
What excipients (inactive ingredients) are in LINACLOTIDE?	LINACLOTIDE excipients list
DailyMed Link:	LINACLOTIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LINACLOTIDE

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LINACLOTIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Florida	PHASE1
Haifeng Lan	PHASE4
Jinling Hospital, China	N/A

See all LINACLOTIDE clinical trials

Generic filers with tentative approvals for LINACLOTIDE

Applicant	Application No.	Strength	Dosage Form
		72MCG	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LINACLOTIDE

Drug Class	Guanylate Cyclase-C Agonist
Mechanism of Action	Guanylate Cyclase Activators

Anatomical Therapeutic Chemical (ATC) Classes for LINACLOTIDE

A06AX	Other drugs for constipation
A06A	DRUGS FOR CONSTIPATION
A06	DRUGS FOR CONSTIPATION
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for LINACLOTIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LINZESS	Capsules	linaclotide	72 mcg	202811	1	2017-11-07
LINZESS	Capsules	linaclotide	145 mcg and 290 mcg	202811	4	2016-08-30

US Patents and Regulatory Information for LINACLOTIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	LINACLOTIDE	linaclotide	CAPSULE;ORAL	209611-002	Feb 7, 2023		DISCN	No	No
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017		RX	Yes	Yes					Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-002	Aug 30, 2012		RX	Yes	No					Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012		RX	Yes	Yes
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012		RX	Yes	Yes
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012		RX	Yes	Yes					Y

Expired US Patents for LINACLOTIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-002	Aug 30, 2012

EU/EMA Drug Approvals for LINACLOTIDE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Constella	linaclotide	EMEA/H/C/002490Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.	Authorised	no	no	no	2012-11-26

International Patents for LINACLOTIDE

Country	Patent Number	Title	Estimated Expiration
Canada	2808091
Canada	3040415
Cyprus	1122853
Denmark	2603232
European Patent Office	2603232	FORMULATIONS STABLES DE LINACLOTIDE (STABLE FORMULATIONS OF LINACLOTIDE)
European Patent Office	3626253	FORMULATIONS STABLES DE LINACLOTIDE (STABLE FORMULATIONS OF LINACLOTIDE)

Supplementary Protection Certificates for LINACLOTIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1594517	C300593	Netherlands		PRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
1594517	92200	Luxembourg		PRODUCT NAME: LINACLOTIDE ET TOUTE FORME THERAPEUTIQUE EQUIVALENTE DE CELUI-CI, PROTEGE PAR LE BREVET DE BASE, Y COMPRIS DES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/12/801/001-004 20121126
1594517	SPC/GB13/032	United Kingdom		PRODUCT NAME: LINACLOTIDE; REGISTERED: UK EU/1/12/801/001 20121128; UK EU/1/12/801/002 20121128; UK EU/1/12/801/003 20121128; UK EU/1/12/801/004 20121128
1594517	C20130011 00400	Estonia		PRODUCT NAME: LINAKLOTIID;REG NO/DATE: K(2012)8832 (LOPLIK) 28.11.2012
2246360	23/2013	Austria		PRODUCT NAME: LINACLOTID UND PHARMAZEUTISCH ANNEHMBARE SALZE HIERVON; REGISTRATION NO/DATE: EU/1/12/801/001-004 (MITTEILUNG) 20121128
1594517	24/2013	Austria		PRODUCT NAME: LINACLOTID UND PHARMAZEUTISCH ANNEHMBAREN SALZE HIERVON; REGISTRATION NO/DATE: EU/1/12/801/001-004 (MITTEILUNG) 20121128

Market Dynamics and Financial Trajectory for Linaclotide

Last updated: March 5, 2026

What is the current market size and growth rate for Linaclotide?

Linaclotide, marketed primarily under the brand name Linzess, is a guanylate cyclase-C agonist approved since 2012 for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The global outlook shows consistent growth driven by increasing prevalence of GI disorders and expanding therapeutic indications.

• The global market for Linaclotide was estimated at $1.1 billion in 2022.
• Compound annual growth rate (CAGR): approximately 6.2% from 2023 to 2028.
• North America accounts for roughly 70% of sales, driven by high diagnosis rates and reimbursement.
• Europe and Asia-Pacific regions are expanding at CAGRs of 5.8% and 7.1%, respectively.

How does Linaclotide’s market positioning compare within its class?

Linaclotide faces competition from other GI motility agents like polyethylene glycol, prucalopride, and eluxadoline. Its unique mechanism of action—stimulating intestinal fluid secretion—positions it as a targeted therapy for specific constipation subtypes.

• Market share (2022): Linzess holds approximately 60% of prescription GI disorder treatments.
• Brand loyalty: A significant proportion of prescriptions originate from gastroenterologists.

What are the key drivers influencing its financial trajectory?

Drivers include:

• Growing prevalence of IBS-C and CIC: Estimated at 10-15% of the global population for IBS and 14% for CIC.
• Expanding indications: Research exploring use in pediatric populations and other bowel disorders.
• Increasing awareness and diagnosis: Better diagnostic tools and reduced stigma promote therapy adoption.
• Pricing and reimbursement policies: Variability influences sales; premium pricing persists due to novel mechanism and clinical efficacy.

What are potential risk factors impacting the market?

• Patent expiration: Expiry in the US is anticipated around 2030, opening markets to generics.
• Generic competition: Multiple companies have filed abbreviated new drug applications (ANDAs) for generic formulations.
• Regulatory hurdles: Potential delays or restrictions on off-label uses could affect revenue.
• Market saturation: Narrow indication scope limits growth beyond current approved uses.

How do recent sales and revenues trend?

• 2020: Approximately $1 billion in global sales.
• 2021–2022: Growth driven by increased new patient initiations and expanded insurance coverage.
• Projected 2023–2028: Steady growth with a potential slowdown post-patent expiry.

What are the key financial milestones and estimates?

Year	Global Sales (USD billion)	Growth Rate	Remarks
2020	1.0	—	Baseline, initial launch
2022	1.1	6.2% CAGR	Market expansion
2025 (est.)	1.45	—	Post-expansion phase
2030 (est.)	1.8 (assuming no generics)	—	Patent expiry approaches

What is the impact of patent expiry and generic competition?

Patent expiry expected around 2030 in the US, with patent protections ending in Europe by 2028. Generics could enter the market at a significant discount, reducing premium pricing and lowering revenue.

• Estimated revenue decline post-generic entry: 40–60% within 1–2 years.
• Companies are exploring formulations, combination therapies, or new indications to mitigate revenue loss.

Which companies are key players?

• AbbVie: Developed Linaclotide, owns the original patent.
• Teva Pharmaceutical Industries: Filed ANDA for generic versions.
• Mylan (now part of Viatris): Also engaged in generic filings.
• Other biotech firms: Exploring alternative therapies targeting similar pathways.

What are future prospects?

• Development of long-acting formulations or combination therapies.
• Expansion into pediatric populations or other gastrointestinal conditions.
• Use of real-world evidence to support broader indications.
• Potential market growth driven by such innovations could offset losses from patent erosion.

Key Takeaways

• Market size in 2022 at ~$1.1 billion; expected to grow at 6.2% annually through 2028.
• Dominant in North America, with expanding presence in Europe and Asia.
• Growth driven by disease prevalence, increased diagnosis, and expanding indications.
• Patent expiry around 2030 threatens revenue stability; generic competition imminent.
• Companies are exploring new formulations and indications to sustain market share.

FAQs

1. When will generic versions of Linaclotide likely enter the market?
Around 2030 in the US, following patent expiration.

2. Are there any approved alternatives for IBS-C and CIC?
Yes. Prucalopride and eluxadoline are approved for some indications, but Linaclotide maintains a significant share due to its efficacy.

3. What regulatory challenges could impact Linaclotide’s future?
Off-label use restrictions, delayed approvals for new indications, or safety concerns could affect sales.

4. How are manufacturers attempting to extend Linaclotide’s market life?
By developing new formulations, exploring additional indications, and investing in real-world evidence studies.

5. What’s the outlook for the Asian market?
High growth potential with CAGR around 7.1%, driven by rising awareness and diagnostic rates.

---

References

1. MarketWatch. (2023). Global Linaclotide market size and forecast.
2. IQVIA. (2022). U.S. prescription and sales data for GI therapeutics.
3. European Medicines Agency. (2022). Linzess marketing authorization.
4. FDA. (2022). Patent expiration dates and generic filing reports.
5. Reports and analyses on GI disorder prevalence and drug approval trends (2020-2023).